DAY ONE🚨 #GUARDSymposium2025 Presenting Roberto Iacovelli 🇮🇹 on How to Treat Patients in 2nd Line after progression to TKI+IO #KidneyCancer Tom Powles Syed A Hussain Matt Galsky Andrea Necchi Félix Guerrero-Ramos Mario AlvarezMaestro Urbano Anido Javier Molina Cerrillo David Lorente Vital Hevia

LIVE DAY 1 #GUARDSymposium2025 Presentation by Dr. Paolo Castellucci🇮🇹 on Staging of localized high risk #ProstateCancer with PET PSMA PSMA PET/CT offers significant advantages in staging high-risk prostate cancer due to its superior accuracy in detecting both nodal and

DAY TWO 🚨 #GUARDSymposium2025 Presentation by Dr. Andrea Necchi 🇮🇹 NeoAdjuvant 🆚Adjuvant🆚PeriOperative Therapy for Muscle Invasive #BladderCancer Tom Powles Syed A Hussain Matt Galsky Andrea Necchi Félix Guerrero-Ramos Mario AlvarezMaestro Urbano Anido Javier Molina Cerrillo David Lorente

Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02) out on Lancet Oncology thelancet.com/journals/lanon… In the phase 3 CONTACT-02 trial, the combination of cabozantinib (a tyrosine kinase inhibitor) and atezolizumab (a PD-L1 inhibitor) was evaluated in men with

#ActiveSurveillance for #ProstateCancer in Göteborg-1 Trial ⏩️25 years FU ✨Failure-free survival rate at 22 yr: 68% ✨PC-specific survival rate at 25 yr: 94% ✨PC-specific survival rate at 24 yr: - 99% for very-low-risk - 92% for low-risk - 85% for intermediate-risk

Dr Giuseppe Cabibbo has a high yield #GIonc review of #IO agents in #hpbcsm #IO has transformed treatment, ⬆️ #OS and creating new #SoC. 💉 Reviews #regimens 🤝 Discusses #synergy with chemo 🚧 Highlight unmet #needs 🔗: cancertreatmentreviews.com/article/S0305-… OncoAlert🚨 ASCO PallOnc Community of Practice

Day TWO #GUARDSymposium2025 🚨 Presentation by Syed A Hussain One line, several options: individualization of treatment in first-line metastatic #BladderCancer Tom Powles Syed A Hussain Matt Galsky Andrea Necchi Félix Guerrero-Ramos Mario AlvarezMaestro Urbano Anido

#SuppOnc commentary from Charles Jiang MD, MPH et al in NatureRevClinOncol Despite ⬆️ pt willingness, #clinicaltrial enrollment is ⬇️ (~7%) 🚧. Using the #COMB 🪮model: ⬆️ capability, opportunity, and motivation can 🦾empower #oncologists to ⬆️ enrollment. 💵🚫🔗:

First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET) thelancet.com/journals/lanon… The VIOLET phase 1/2 trial evaluated the safety of the novel radioligand therapy

Over the next 2 weeks hope to do some quick #video summaries of our #Top10Tips paper for #hpm on #survonc. Hope you enjoy! #pallonc #supponc This is Tip 1⃣ cross team collab 🤝 Gregg Robbins-Welty, MD, MS, HEC-C Larissa Nekhlyudov Nicolas Hart Samina B. Martin, MD Billy Rosa, PhD, MBE, APRN OncoAlert🚨 ASCO PallOnc Community of Practice

New editorial in Supportive Care in Cancer: Springer Journal Takemura Naomi Ph.D. RN discusses as #SurvOnc ⬆️ many face complex challenges Adapting #TreatableTraits model - a personalized approach: 👨‍⚕️clinical 🏋️‍♂️physical 🏃lifestyle, and ⛪️psychospiritual needs 🔗: link.springer.com/article/10.100… Nicolas Hart

Check out #GUARDSymposium2025 ✨‼️✨

Societie International d'Urologie (SIU) is a urological society with more than 17,000 members from over 130 countries globally. This year, the SIU Congress will be held in Edinburgh from 29th October to 1st November. Registration link: siu-urology.org/congress-2025/…

🚨 Ready to take your surgical skills to the next level? Train on hyper-realistic models in our Hands-On Program: Laparoscopic Partial Nephrectomy, endorsed by @siu_urology Learn from expert surgeons and master every step of the procedure. 🔗 Sign-up link in the first comment

The always excellent OncoAlert RoundUp🚨 Exercise in metastatic #ProstateCancer ✨alleviates ADT-related burdens ✨enhances immune response ✨slows disease progression REGISTER HERE 👉 OncoAlert360.com OR buff.ly/p0O1gZ8 #OncoTwitter #UroOnc

Another masterpiece of Aron project. Congrats all authors specially Maite Bourlon and Matteo Santoni

The OncoAlert 🚨 VJ Oncology JOURNAL CLUB This week we have the pleasure to bring you Biagio Ricciuti, MD, PhD of Dana-Farber 🇺🇸 Discussing Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer by Dr.

THE #OncoAlert5k 🚨at #ESMO25 🏃‍♀️🏃‍♂️🏁 A Warm invite to Join us Saturday October 18, 2025 at 7 AM starting at the Brandenburg Gate🇩🇪Berlin Sign Up Coming soon!! #OncoAlertAF Dra. María Natalia Gandur Quiroga Biagio Ricciuti, MD, PhD Emre Yekedüz Hidehito HORINOUCHI Fadi Haddad, MD Al-Ola A Abdallah MD (USMIRC) Jose Fernando Moura, PhD

🥁The most updated epidemiology data in #kidneycancer 👇 doi.org/10.1016/j.euru… OncoAlert European Urology

Neoadjuvant immunotherapy in muscle-invasive bladder cancer is reshaping the standard of care. Our new review explores the latest trials, response rates, and how checkpoint inhibitors may redefine treatment before cystectomy. sciencedirect.com/science/articl… NOSMU Urology